PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32615949-5 2020 RESULTS: Retrospective analysis of the clinical data revealed that the etoposide with G-CSF mobilization group showed the highest yield of CD34+ cells and the lowest change in white blood cell counts during mobilization. Etoposide 71-80 colony stimulating factor 3 Homo sapiens 86-91 32615949-10 2020 CONCLUSION: Collectively, the unique mechanism of etoposide with G-CSF-induced mobilization is associated with IL-8 secretion from the BMSCs, which is responsible for the enhanced proliferation and mobilization of HSCs in the bone marrow; this was not observed with mobilization using cyclophosphamide with G-CSF or G-CSF alone. Etoposide 50-59 colony stimulating factor 3 Homo sapiens 65-70 32615949-10 2020 CONCLUSION: Collectively, the unique mechanism of etoposide with G-CSF-induced mobilization is associated with IL-8 secretion from the BMSCs, which is responsible for the enhanced proliferation and mobilization of HSCs in the bone marrow; this was not observed with mobilization using cyclophosphamide with G-CSF or G-CSF alone. Etoposide 50-59 colony stimulating factor 3 Homo sapiens 307-312 32615949-10 2020 CONCLUSION: Collectively, the unique mechanism of etoposide with G-CSF-induced mobilization is associated with IL-8 secretion from the BMSCs, which is responsible for the enhanced proliferation and mobilization of HSCs in the bone marrow; this was not observed with mobilization using cyclophosphamide with G-CSF or G-CSF alone. Etoposide 50-59 colony stimulating factor 3 Homo sapiens 307-312 32615949-9 2020 In animal studies, the etoposide with G-CSF mobilization group presented higher IL-8-related cytokine and MMP9 expression and lower SDF-1 expression in the BM, compared to the groups not treated with etoposide. Etoposide 23-32 colony stimulating factor 3 Homo sapiens 38-43 32615949-9 2020 In animal studies, the etoposide with G-CSF mobilization group presented higher IL-8-related cytokine and MMP9 expression and lower SDF-1 expression in the BM, compared to the groups not treated with etoposide. Etoposide 200-209 colony stimulating factor 3 Homo sapiens 38-43 18806833-0 2009 EPO in combination with G-CSF improves mobilization effectiveness after chemotherapy with ifosfamide, epirubicin and etoposide and reduces costs during mobilization and transplantation of autologous hematopoietic progenitor cells. Etoposide 117-126 colony stimulating factor 3 Homo sapiens 24-29 21123967-0 2010 Cell cycle-dependent priming action of granulocyte colony-stimulating factor (G-CSF) enhances in vitro apoptosis induction by cytarabine and etoposide in leukemia cell lines. Etoposide 141-150 colony stimulating factor 3 Homo sapiens 39-76 21123967-0 2010 Cell cycle-dependent priming action of granulocyte colony-stimulating factor (G-CSF) enhances in vitro apoptosis induction by cytarabine and etoposide in leukemia cell lines. Etoposide 141-150 colony stimulating factor 3 Homo sapiens 78-83 21123967-1 2010 We investigated the priming effect and mechanism of granulocyte colony-stimulating factor (G-CSF) in chemotherapy with low-dose Ara-C and VP-16 for acute myeloid leukemia. Etoposide 138-143 colony stimulating factor 3 Homo sapiens 52-89 21123967-1 2010 We investigated the priming effect and mechanism of granulocyte colony-stimulating factor (G-CSF) in chemotherapy with low-dose Ara-C and VP-16 for acute myeloid leukemia. Etoposide 138-143 colony stimulating factor 3 Homo sapiens 91-96 21123967-13 2010 G-CSF potentiates Ara-C- and VP-16-induced cytotoxicities through apoptosis induction by mobilizing resting G0-G1-phase cells into S phase. Etoposide 29-34 colony stimulating factor 3 Homo sapiens 0-5 27749622-5 2017 Plerixafor in combination with granulocyte-colony stimulating factor showed its efficacy in mobilizing 6x10 CD34+/kg HSCs able to rescue two HDC cycles of carboplatin-etoposide, leading to stable hematopoietic engraftment. Etoposide 167-176 colony stimulating factor 3 Homo sapiens 31-68 23134856-14 2012 CONCLUSION: Single high-dose etoposide with G-CSF for mobilization of APBSC has a higher achievement ratio, a controllable adverse effect, a promising hematopoiesis recovery, which is an effective and safe mobilizing regimen for patients with hematologic malignancies. Etoposide 29-38 colony stimulating factor 3 Homo sapiens 44-49 19036079-5 2009 This was more notable in children who received idarubicin, fludarabine, ara-C, and granulocyte colony-stimulating factor (IDA-FLAG; ara-C = 7590 mg/m2) (5-year TRM 24 +/- 21% CC vs. 6 +/- 6% AA, 6 +/- 7% AC, P = 0.07) as consolidation therapy compared to idarubicin, dexamethasone, cytarabine, thioguanine, etoposide and daunomycin (IDA-DCTER; ara-C = 800 mg/m2) (5-year TRM 15 +/- 20% CC vs. 8 +/- 6% AA, 4 +/- 6% AC; P = 0.29). Etoposide 307-316 colony stimulating factor 3 Homo sapiens 83-120 16638224-7 2006 It is concluded that high-dose etoposide with G-CSF is an effective and safe mobilizing regimen for autologous peripheral blood stem progenitor cells in patients with hematologic malignancies. Etoposide 31-40 colony stimulating factor 3 Homo sapiens 46-51 18567557-1 2008 BACKGROUND: ESHAP (etoposide/methylprednisolone/cytarabine/cisplatin) plus granulocyte-colony stimulating factor (G-CSF) is an effective regimen of therapy for advanced non-Hodgkin"s lymphoma (NHL) and peripheral blood progenitor cell (PBPC) mobilization. Etoposide 19-28 colony stimulating factor 3 Homo sapiens 114-119 17918772-0 2008 Continuous drip infusion of low dose cytarabine and etoposide with granulocyte colony-stimulating factor for elderly patients with acute myeloid leukaemia ineligible for intensive chemotherapy. Etoposide 52-61 colony stimulating factor 3 Homo sapiens 67-104 11466671-1 2001 BACKGROUND: To address the feasibility and outcome of moderate dose intensification with granulocyte-colony stimulating factor (G-CSF) for patients with aggressive non-Hodgkin lymphoma (NHL), the Cancer and Leukemia Group B (CALGB) conducted two studies evaluating dose-escalated cyclophosphamide and etoposide in the cyclophosphamide, doxorubicin, vincristine, prednisone, etoposide (CHOPE) regimen. Etoposide 374-383 colony stimulating factor 3 Homo sapiens 128-133 15814645-0 2005 A phase I clinical, pharmacologic, and biologic study of thrombopoietin and granulocyte colony-stimulating factor in children receiving ifosfamide, carboplatin, and etoposide chemotherapy for recurrent or refractory solid tumors: a Children"s Oncology Group experience. Etoposide 165-174 colony stimulating factor 3 Homo sapiens 76-113 14871251-3 2004 Strikingly, high-dose cytarabine and etoposide plus granulocyte colony stimulating factor (G-CSF) mobilized PBSC harvests from acute myeloid leukaemia (AML) patients containing the highest number of myeloid lin(neg)CD11c(pos) DC (mean: 7.04 x 106/kg, range: 1.46-19.67) which was 18.1-fold higher than in non-AML patients mobilized using chemotherapy (CT) regimens plus G-CSF. Etoposide 37-46 colony stimulating factor 3 Homo sapiens 370-375 12416471-9 2002 Several regimens have been proposed for stem cells mobilization including: High-dose cyclophosphamide and G or GM-CSF, G-CSF alone, and cyclophosphamide and etoposide with G-CSF... ect.. Further attempts to improve the results of autotransplantation have included intensification with tandem transplantations (double transplants) and reduction of tumor cells in stem cell infusion. Etoposide 157-166 colony stimulating factor 3 Homo sapiens 172-177 11466671-1 2001 BACKGROUND: To address the feasibility and outcome of moderate dose intensification with granulocyte-colony stimulating factor (G-CSF) for patients with aggressive non-Hodgkin lymphoma (NHL), the Cancer and Leukemia Group B (CALGB) conducted two studies evaluating dose-escalated cyclophosphamide and etoposide in the cyclophosphamide, doxorubicin, vincristine, prednisone, etoposide (CHOPE) regimen. Etoposide 301-310 colony stimulating factor 3 Homo sapiens 128-133 10774251-5 2000 The patient was treated with continuous-drip infusion of low-dose cytarabine and etoposide with G-CSF (AVG therapy). Etoposide 81-90 colony stimulating factor 3 Homo sapiens 96-101 11205919-0 2001 A phase I clinical, pharmacological, and biological trial of interleukin 6 plus granulocyte-colony stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent/refractory solid tumors: enhanced hematological responses but a high incidence of grade III/IV constitutional toxicities. Etoposide 153-162 colony stimulating factor 3 Homo sapiens 80-117 10982237-0 2000 Mobilization with etoposide and granulocyte colony-stimulating factor can replace bone marrow harvesting in patients with malignant lymphoma who previously failed to mobilize sufficient stem cells with cyclophosphamide and G-CSF. Etoposide 18-27 colony stimulating factor 3 Homo sapiens 223-228 10637255-4 2000 Preliminary, nonrandomized feasibility studies showed that doxorubicin, cyclophosphamide, and etoposide (ACE) could be given every 2 (instead of the usual 3) weeks with granulocyte colony-stimulating factor (G-CSF) (lenograstim; Chugai-Rh?one-Poulenc, Tokyo, Japan) support. Etoposide 94-103 colony stimulating factor 3 Homo sapiens 169-206 10637255-4 2000 Preliminary, nonrandomized feasibility studies showed that doxorubicin, cyclophosphamide, and etoposide (ACE) could be given every 2 (instead of the usual 3) weeks with granulocyte colony-stimulating factor (G-CSF) (lenograstim; Chugai-Rh?one-Poulenc, Tokyo, Japan) support. Etoposide 94-103 colony stimulating factor 3 Homo sapiens 208-213 10414907-4 1999 Here we report the results of using etoposide as a mobilizing agent in 16 patients with primary resistant or relapsed malignant lymphoma who had failed prior mobilization of peripheral blood stem cells (PBSC) with cyclophosphamide (4 g/m2) followed by G-CSF. Etoposide 36-45 colony stimulating factor 3 Homo sapiens 252-257 10706456-0 1999 Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin"s lymphoma. Etoposide 30-39 colony stimulating factor 3 Homo sapiens 45-50 9401275-3 1997 A total of 16 patients were consecutively treated with granulocyte colony-stimulating factor (G-CSF)-combined high-dose chemotherapy (busulfan, etoposide and Ara-C) followed by autotransplantation of peripheral blood progenitor cells, which had been collected after the consolidation chemotherapy. Etoposide 144-153 colony stimulating factor 3 Homo sapiens 94-99 9764585-1 1998 High-dose etoposide (2.0-2.4 g m(-2)) with granulocyte colony-stimulating factor (G-CSF) is an effective strategy to mobilize peripheral blood progenitor cells (PBPCs), although in some patients this is associated with significant toxicity. Etoposide 10-19 colony stimulating factor 3 Homo sapiens 43-80 9764585-1 1998 High-dose etoposide (2.0-2.4 g m(-2)) with granulocyte colony-stimulating factor (G-CSF) is an effective strategy to mobilize peripheral blood progenitor cells (PBPCs), although in some patients this is associated with significant toxicity. Etoposide 10-19 colony stimulating factor 3 Homo sapiens 82-87 9764585-11 1998 These data suggest that high-dose etoposide with G-CSF is an efficient mobilization regimen in the majority of heavily pretreated patients, including those who have previously failed on high-dose cyclophosphamide with G-CSF. Etoposide 34-43 colony stimulating factor 3 Homo sapiens 49-54 9764585-11 1998 These data suggest that high-dose etoposide with G-CSF is an efficient mobilization regimen in the majority of heavily pretreated patients, including those who have previously failed on high-dose cyclophosphamide with G-CSF. Etoposide 34-43 colony stimulating factor 3 Homo sapiens 218-223 9989882-3 1998 As mobilising chemotherapy, cyclophosphamide, etoposide, doxorubicin and cytosine arabinoside were the drugs most frequently used in association with G-CSF for a total of 47 courses. Etoposide 46-55 colony stimulating factor 3 Homo sapiens 150-155 9592981-5 1998 RESULTS: G-CSF support significantly reduced the frequency of day-1 drug dose reductions (p < 0.001) and of chemotherapy delays (p < 0.001), and improved the actual delivered doses of adriamycin, cyclophosphamide and etoposide (p < 0.02). Etoposide 223-232 colony stimulating factor 3 Homo sapiens 9-14 9815838-13 1997 Sequential IL-3/G-CSF given prior to and following high-dose etoposide and cyclophosphamide is safe and is a feasible strategy to compare in prospective randomized trials to patients treated with only postchemotherapy IL-3 and G-CSF and to patients treated with peripheral blood stem cell support. Etoposide 61-70 colony stimulating factor 3 Homo sapiens 16-21 9427795-0 1997 A new schedule for etoposide, epidoxorubicin and cisplatin with granulocyte colony stimulating factor for advanced gastric cancer: a feasibility study. Etoposide 19-28 colony stimulating factor 3 Homo sapiens 64-101 9167751-0 1997 Standard-dose recombinant human granulocyte colony-stimulating factor (rhG-CSF) allows safe and repeated administration of high-dose cyclophosphamide, etoposide, and cisplatin (CEP). Etoposide 151-160 colony stimulating factor 3 Homo sapiens 32-69 9364868-0 1997 [Acute myeloblastic leukemia showing pronounced skin infiltration during administration of low-dose cytarabine and etoposide with granulocyte colony-stimulating factor]. Etoposide 115-124 colony stimulating factor 3 Homo sapiens 130-167 9037362-1 1996 PURPOSE: To identify the highest possible dose of cyclophosphamide (C) and etoposide (E) to be given with high-dose doxorubicin (D) and filgrastim (G-CSF) but without stem cell support in high-risk non-Hodgkin"s lymphoma. Etoposide 75-84 colony stimulating factor 3 Homo sapiens 148-153 9547675-10 1997 CONCLUSIONS: In pretreated patients, the maximum tolerated dose of etoposide phosphate with G-CSF is 1938 mg/m2 (equivalent to etoposide 1700 mg/m2). Etoposide 67-76 colony stimulating factor 3 Homo sapiens 92-97 8946866-12 1996 CONCLUSION: In 30 women with primary advanced ovarian cancer, G-CSF allowed a 50% dose escalation of etoposide and ifosfamide from 0.8 to 1.2 dose intensity. Etoposide 101-110 colony stimulating factor 3 Homo sapiens 62-67 8580054-0 1995 Increasing and planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) by adding recombinant human methionyl granulocyte colony-stimulating factor (G-CSF; filgrastim) in the treatment of small cell lung cancer (SCLC). Etoposide 75-84 colony stimulating factor 3 Homo sapiens 168-173 7474409-1 1995 A study was conducted to evaluate the impact of cisplatin, doxorubicin, cyclophosphamide and etoposide (PACE) with granulocyte colony-stimulating factor (G-CSF) on advanced thymoma or thymic cancer. Etoposide 93-102 colony stimulating factor 3 Homo sapiens 115-152 8599980-9 1996 G-CSF significantly enhanced the cytotoxic effect of daunorubicin, mitoxantrone, etoposide and Ara-C by 20-40%, which GM-CSF and IL-3 showed a significantly increased toxicity for Ara-C only. Etoposide 81-90 colony stimulating factor 3 Homo sapiens 0-5 8826913-0 1995 Phase I/II study of carboplatin and oral etoposide with granulocyte-colony stimulating factor in advanced nonsmall cell lung cancer. Etoposide 41-50 colony stimulating factor 3 Homo sapiens 56-93 7536433-0 1995 The feasibility of using glycosylated recombinant human granulocyte colony-stimulating factor (G-CSF) to increase the planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) in the treatment of small cell lung cancer. Etoposide 178-187 colony stimulating factor 3 Homo sapiens 56-93 7536433-0 1995 The feasibility of using glycosylated recombinant human granulocyte colony-stimulating factor (G-CSF) to increase the planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) in the treatment of small cell lung cancer. Etoposide 178-187 colony stimulating factor 3 Homo sapiens 95-100 1280674-0 1992 Granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor infusion makes high-dose etoposide a safe outpatient regimen that is effective in lymphoma and myeloma patients. Etoposide 115-124 colony stimulating factor 3 Homo sapiens 52-89 7521905-0 1994 Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer. Etoposide 50-59 colony stimulating factor 3 Homo sapiens 83-120 7692928-0 1993 Peripheral blood progenitor cells mobilized by chemotherapy plus granulocyte-colony stimulating factor accelerate both neutrophil and platelet recovery after high-dose VP16, ifosfamide and cisplatin. Etoposide 168-172 colony stimulating factor 3 Homo sapiens 65-102 7687859-4 1993 G-CSF (5 micrograms/kg) was administered during the recovery phase in 6/14 courses with Ara-C/Etop and in 4/13 courses with Ara-C/Mit. Etoposide 94-98 colony stimulating factor 3 Homo sapiens 0-5 7530630-4 1994 Two comparative studies have demonstrated that prophylactic administration of filgrastim 230 micrograms/m2/day significantly reduces the incidence, duration and severity of neutropenia in patients with previously untreated small-cell lung cancer receiving standard-dose chemotherapy with CDE (cyclophosphamide, doxorubicin plus etoposide). Etoposide 328-337 colony stimulating factor 3 Homo sapiens 78-88 7514494-2 1994 In this study, we show that administration of recombinant human (rh) G-CSF decreased the in vitro and in vivo cytotoxic effects of Adriamycin or etoposide on L1210 murine leukemic cells with receptors for rhG-CSF. Etoposide 145-154 colony stimulating factor 3 Homo sapiens 69-74 7685138-0 1993 [Effect of recombinant human granulocyte colony stimulating factor in patients with transitional cell carcinoma of the urothelium receiving methotrexate, etoposide and cisplatinum combination chemotherapy]. Etoposide 154-163 colony stimulating factor 3 Homo sapiens 29-66 7685138-1 1993 We determined the effective method of administration of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in patients with transitional cell carcinoma of the urothelium receiving methotrexate, etoposide and cisplatinum (MEC) therapy. Etoposide 209-218 colony stimulating factor 3 Homo sapiens 74-111 1699657-5 1990 According to in vitro cytotoxic assay, the sensitivity of G-CSF-stimulated cells to intercalating (daunorubicin) and nonintercalating (etoposide) topo II-targeting drugs increased significantly, whereas no enhancement of sensitivity was observed with an alkylating agent (4-hydroperoxycyclophosphamide). Etoposide 135-144 colony stimulating factor 3 Homo sapiens 58-63 33590721-1 2021 BACKGROUND: The aim of this study was to discuss the safety and efficacy of administering reduced doses (3 mg) of pegylated recombinant human granulocyte-colony stimulating factor (PEG-rhG-CSF) at approximately 24 h or up to three days following treatment with etoposide and cisplatin (EP). Etoposide 261-270 colony stimulating factor 3 Homo sapiens 142-179 1691246-1 1990 This manuscript summarizes our experience with recombinant human granulocyte colony-stimulating factor (rhG-CSF) with high-dose Cytoxan, carmustine and etoposide (CBV in Hodgkin"s disease). Etoposide 152-161 colony stimulating factor 3 Homo sapiens 65-102 34844181-0 2021 Prophylactic granulocyte-colony stimulating factor in patients with lung neuroendocrine carcinoma receiving platinum agents plus etoposide. Etoposide 129-138 colony stimulating factor 3 Homo sapiens 13-50 35155259-4 2022 Methods: This research retrospectively studied mobilization efficacy and safety using etoposide combined with Cytarabine (etoposide 50-100 mg/m2, qd d1-3; AraC 0.5 g/m2, q12h d1~3) plus G-CSF (5 microg/kg/day, from d5 until the day of apheresis) in 128 patients with MM. Etoposide 86-95 colony stimulating factor 3 Homo sapiens 186-191 33880064-2 2021 In this study, we aimed to evaluate the efficacy of polyethylene glycol recombinant granulocyte colony-stimulating factor (PEG-rhG-CSF) compared with short-acting rhG-CSF in the dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) regimen. Etoposide 192-201 colony stimulating factor 3 Homo sapiens 84-121